Obesity framed as chronic

Obesity is increasingly being treated as a chronic disease, with medical groups framing it less like a short-term diet problem and more like high blood pressure or asthma that needs ongoing care. (ajmc.com) That shift has been building for years. The American Medical Association recognized obesity as a chronic disease in 2013, and a 2014 guideline from the American College of Cardiology, American Heart Association, and The Obesity Society set out long-term management standards for adults with overweight and obesity. (ajmc.com) In plain terms, the newer model starts with nutrition, physical activity, sleep, stress management, and behavioral support, then adds medicines or surgery when patients meet clinical thresholds. The review in *The American Journal of Managed Care* describes lifestyle therapy, anti-obesity drugs, and bariatric surgery as the three main treatment pillars. (ajmc.com) Drug treatment is no longer treated as a last-resort add-on in every case. The American Gastroenterological Association said in a 2022 guideline that adults with obesity, or overweight with weight-related complications, should use pharmacological treatment together with lifestyle changes rather than lifestyle changes alone. (gastrojournal.org) The threshold for that care is usually measured with body mass index, or BMI, a height-and-weight screening tool. The AGA guideline covers adults with BMI of 30 kilograms per square meter or higher, or 27 or higher with weight-related comorbidities, after an inadequate response to lifestyle intervention. (gastro.org) Specialist groups have also been changing the language around the condition. The American Association of Clinical Endocrinology uses the term “adiposity-based chronic disease” in its obesity algorithms and says the framework is meant to reflect chronic care and shared decision-making rather than one-time weight-loss advice. (pro.aace.com) That approach has shaped how some health systems use newer medicines. In England, the National Institute for Health and Care Excellence recommended semaglutide in March 2023 only alongside diet and physical activity and within specialist weight-management services, and recommended tirzepatide in December 2024 for eligible adults with obesity and at least one weight-related comorbidity. (nice.org.uk 1) (nice.org.uk 2) Clinics and hospitals are now being pushed toward follow-up models that look more like chronic disease management: repeated visits, medication monitoring, escalation when treatment fails, and long-term maintenance after weight loss. The AJMC review says that means moving away from brief dieting advice and toward sustained care plans. (ajmc.com) The change does not erase debate over access, cost, side effects, or stigma. But across recent guidelines, the center of care has moved from telling patients to “try harder” to treating obesity as a condition that often needs continuing medical treatment. (pro.aace.com) (ajmc.com)